VAN WIJMEERSCH, Bart

Email Alert RSS Feed

Profile

Full Name
VAN WIJMEERSCH, Bart
Email
bart.vanwijmeersch@uhasselt.be
 
Loading... 5 0 5 0 false
Loading... 6 0 5 0 false

Publications

Results 141-160 of 198 (Search time: 0.006 seconds).

show all
Issue DateTitleContributor(s)TypeCat.
1412018Lack of apparent association between lymphocyte pharmacodynamics and clinical or MRI disease activity in alemtuzumab-treated relapsing-remitting Multiple Sclerosis patients through 6 years: CARE-MS extensionVAN WIJMEERSCH, Bart; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; Jacobs, Alessia; Wiendl, H.Journal ContributionM
1422018Lack of apparent association between lymphocyte repopulation kinetics and autoimmune events in alemtuzumab-treated patients with relapsing-remitting Multiple Sclerosis through 6 years: CARE-MS extensionWiendl, H.; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; JACOBS, Andre; VAN WIJMEERSCH, BartJournal ContributionM
1432018Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study)VAN WIJMEERSCH, Bart; Vermersch, P.; Boyko, A.; de Seze, J.; Hartung, H. -P.; Havrdova, E. Kubala; Inshasi, J. Said; McCombe, P.; Montalban, X.; Pozzili, C.; Melanson, M.; Daizadeh, N.; Rodriguez, C.; Selmaj, K.Journal ContributionM
1442018Twelve Weeks of Medium-Intensity Exercise Therapy Affects the Lipoprotein Profile of Multiple Sclerosis Patients.JORISSEN, Winde; VANMIERLO, Tim; WENS, Inez; SOMERS, Veerle; VAN WIJMEERSCH, Bart; BOGIE, Jeroen; Remaley, Alan; OP 'T EIJNDE, Bert; HENDRIKS, JeromeJournal ContributionA1
1452018Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patientsMONTES DIAZ, Gwendoline; FRAUSSEN, Judith; VAN WIJMEERSCH, Bart; Hupperts, R.; SOMERS, VeerleJournal ContributionA1
1462018Walking endurance and perceived symptom severity after a single maximal exercise test in persons with mild disability because of multiple sclerosis.MOUMDJIAN, Lousin; GERVASONI, Elisa; VAN HALEWYCK, Florian; OP 'T EIJNDE, Bert; WENS, Inez; VAN GEEL, Fanny; VAN WIJMEERSCH, Bart; FEYS, Peter; VAN ASCH, PaulJournal ContributionA1
1472017Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation studyCosters, Lars; Gielen, Jeroen; Eelen, Piet L.; van Schependom, Jeroen; Laton, Jorne; Van Remoortel, Ann; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Seeldrayers, Pierrette; Haelewyck, Marie-Claire; D'Haeseleer, Miguel; D'hooghe, Marie-Beatrice; Langdon, Dawn; Nagels, GuyJournal ContributionA1
1482017Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study.Costers, Lars; Gielen, Jeroen; Eelen, Piet L.; Van Schependom, Jeroen; Laton, Jorne; Van Remoortel, Ann; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Seeldrayers, Pierrette; Haelewyck, Marie-Claire; D'Haeseleer, Miguel; D'hooghe, Marie-Beatrice; Langdon, Dawn; Nagels, GuyJournal ContributionM
92017Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammationVANHEUSDEN, Marjan; BROUX, Bieke; Welten, Suzanne P. M.; PEETERS, Liesbet; Panagioti, Eleni; VAN WIJMEERSCH, Bart; SOMERS, Veerle; STINISSEN, Piet; Arens, Ramon; HELLINGS, NielsJournal ContributionA1
102017Teri-DYNAMIC: Exploring the impact of teriflunomide on immune cell population size, receptor repertoire, and function in patients with RRMSWiendl, Heinz; Gross, Catharina C.; Eschborn, Melanie; Weisser, Linda; Posevitz-Fejfar, Anita; Schulte-Mecklenbeck, Andreas; VAN WIJMEERSCH, Bart; Hupperts, Raymond; Brette, Sandrine; Turner, Timothy J.; Bar-Or, Amit; Klotz, LuisaJournal ContributionM
112017Cytotoxic CD4+T Cells Drive Multiple Sclerosis ProgressionPEETERS, Liesbet; VANHEUSDEN, Marjan; SOMERS, Veerle; VAN WIJMEERSCH, Bart; STINISSEN, Piet; BROUX, Bieke; HELLINGS, NielsJournal ContributionA1
122017Comparative clinical efficacy of alemtuzumab and ocrelizumab in patients with relapsing-remitting multiple sclerosis: Number needed to treat analysesComi, G.; Boster, A.; Alroughani, R.; Berkovich, R.; Izquierdo, G.; Kantor, D.; Laganke, C.; Limmroth, V.; Macdonell, R.; Moreau, T.; Sharrack, B.; Wiendl, H.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Melanson, M.; Freedman, M. S.Journal ContributionM
132016Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis PatientsCLAES, Nele; FRAUSSEN, Judith; VANHEUSDEN, Marjan; HELLINGS, Niels; STINISSEN, Piet; VAN WIJMEERSCH, Bart; Hupperts, Raymond; SOMERS, VeerleJournal ContributionA1
142016Upper Limb Rehabilitation in People With Multiple Sclerosis: A Systematic ReviewLAMERS, Ilse; MARIS, Anneleen; SEVERIJNS, Deborah; Dielkens, Wouter; Geurts, Sander; VAN WIJMEERSCH, Bart; FEYS, PeterJournal ContributionA1
152016Durable reduction in MRI disease activity with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS I studyArnold, D. L.; Barnett, M.; Comi, G.; Giovannoni, G.; Pelletier, D.; Rovira, A.; Schippling, S.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Traboulsee, A.Journal ContributionM
162016Effects of teriflunomide treatment on the CD4(+) T-cell receptor repertoire in patients with relapsing-remitting MSKlotz, Luisa; Lindner, Maren; Gross, Catherina C.; Eschborn, Melanie; Posevitz-Fejfar, Anita; Schulte-Mecklenbeck, Andreas; Meuth, S. G.; VAN WIJMEERSCH, Bart; Hupperts, Raymond; Maeurer, M.; Stangel, M.; Lang, M.; Tackenberg, B.; Lysandropoulos, A.; Decoo, D.; Eveslage, M.; Turner, Timothy J.; Jagerschmidt, A.; Bar-Or, Amit; Wiendl, HeinzJournal ContributionM
172016Brain atrophy by automated MRI reading in long-term natalizumab treated patients: Real world data suggests brain atrophy rates in range of healthy individualsHorakova, Dana; Uher, T.; Vaneckova, M.; Krasensky, J.; Seidl, Z.; van Pesch, V.; Lysandropoulos, A.; VAN WIJMEERSCH, Bart; Ribbens, A.; van Hecke, W.; Dong, Q.; Farkas, M.; Hyde, R.; Koendgen, H.Journal ContributionM
182016Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)Oreja-Guevara, C.; Alroughani, R.; Brassat, D.; Boyko, A. N.; McCombe, P.; Steingo, B.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.; Vermersch, P.Journal ContributionM
192016Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).Coles, A. J.; Boyko, A. N.; Cohen, J. A.; De Seze, J.; Fox, E. J.; Havrdova, E.; Hartung, H. -P.; Inshasi, J. S.; McCombe, P.; Selmaj, K. W.; Vermersch, P.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.; Montalban, X.Journal ContributionM
202016Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatmentBermel, R.; Comi, G.; Eralinna, J. -P.; Leist, T. P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Bernasconi, C.; Buffels, R.; Csoboth, C.; Han, J.; Musch, B.; Vermersch, P.Journal ContributionM
show all